Apr. 12 2024
Source Page: Non-technical summaries granted in 2024Found: Mice are able to clear these bacteria quickly (in health), less quickly in vascular disease.
Mar. 19 2024
Source Page: FOI responses published by MOD: week commencing 18 March 2024Found: Peripheral vascular diseases 10. Raynaud’s phenomenon or vasospastic disease.
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 29 May 2023Found: , Cerebral thrombosis, Cerebral vascular occlusion, Cerebral vasoconstriction, Cerebral venous thrombosis
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 27 March 2023Found: associated with neurological disorders and peripheral vascular disease in the lower limbs.
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: 2 Raynauds syndrome 2 Peripheral arterial occlusive disease 2 Peripheral venous disease (venous insufficiency
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: findings abnormal Gastrointestinal sounds abnormal 1 0 Colitis (excl infective) Crohn's disease
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: thrombosis and Ret inal vascular occl usion.
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023Found: VAERD Vaccine -associated enhanced respiratory disease VTE Venous thromboembolism VITT Vaccine
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023Found: the study data sources 3 11-Apr- 20239.3.2.1 Safety OutcomesTable 1, AESI ‘Thrombocytopenia with venous
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023Found: deleted “thrombocytopenia, venous thromboembolism” from the list of AESIsThese three names refe r